A landmark collaboration between Insilico Medicine and Eli Lilly leverages AI to accelerate drug discovery for aging-related diseases, with recent data showing reduced costs and faster development. Th...
Senolytic and senomorphic therapies, including Rubedo’s RLS-1496 in Phase 1 trials, target senescent cells to treat aging diseases, boosted by AI-driven discovery and rising investment. New seno...
